Myelofibrosis is a rare cancer that affects your bone marrow, the spongy tissue inside some of your bones. In a healthy person, stem cells in the bone marrow make the red blood cells, white blood ...

What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical ...

MOMENTUM was a phase III, global, multicentre, randomised, double-blind study investigating momelotinib versus danazol in patients with myelofibrosis who were symptomatic and anemic and had been ...

Fedratinib (Inrebic) is available on the NHS. It is a possible treatment for disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential ...

It can be used in both markets in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. In the pivotal MOMENTUM clinical ...

After turning down routine NHS funding of Bristol-Myers Squibb's Inrebic for bone marrow disorder myelofibrosis earlier this year, NICE now says the drug can be made available via the Cancer Drugs ...